DexCom (DXCM) Tops Q2 EPS by 8c

DexCom (NASDAQ: DXCM) reported Q2 EPS of ($0.10), $0.08 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $242.5 million versus the consensus estimate of $205.68 million.

GUIDANCE:

DexCom sees FY2018 revenue of $925 million, versus the consensus of $862.2 million.

For earnings history and earnings-related data on DexCom (DXCM) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Empire Petroleum posts $11.1M revenue in Q2 2026, narrows net loss
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c